Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice
- PMID: 12874031
Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice
Abstract
In Drosophila and Caenorhabditis elegans, kinase suppressor of ras (KSR) positively modulates Ras/Raf-mitogen-activated protein kinase (MAPK) signaling. The precise signaling mechanism of mammalian KSR1 and its role in Ras-mediated transformation, however, remain uncertain. To gain insight into KSR1 function in vivo, we generated mice homozygous null for KSR1. ksr1-/- mice are viable and without major developmental defects. However, an unusual disorganized hair follicle phenotype manifest in epidermal growth factor receptor knockout mice is recapitulated in ksr1-/- mice, providing genetic support for the notion that epidermal growth factor receptor, Ras, and KSR1 are on the same signaling pathway in mammals. Furthermore, ksr1-/- mice allow for the definition of KSR1-dependent and -independent mechanisms of c-Raf-1 activation. In embryonic fibroblasts, epidermal growth factor and 12-O-tetradecanoylphorbol-13-acetate activated the MAPK cascade to a similar extent, yet only c-Raf-1 activation by epidermal growth factor depended on KSR1. Moreover, whereas the genesis of polyomavirus middle T antigen (MT)-driven mammary cancer appears independent of KSR1, KSR1 is obligate for v-Ha-ras-mediated skin tumor formation. The growth of MT-driven mammary tumor was moderately slowed in ksr1-/- mice, however, consistent with a decreased rate of proliferation of ksr1-/- cells (T cells and embryonic fibroblasts). Nonetheless, all ksr1-/- animals succumbed to mammary cancer. In contrast, papilloma formation in Tg.AC mice, resulting from skin-specific v-Ha-ras expression, was completely abrogated in the ksr1-/- background. Hence, MT-driven mammary tumor genesis, which is signaled through src and phosphatidylinositol 3'-kinase, appears KSR1 independent, whereas v-Ha-ras-mediated skin cancer, signaled through the Raf-1/MAPK cascade, requires KSR1. These results suggest KSR1 may represent a therapeutic target for Ras/MAPK signaling of human tumorigenesis.
Similar articles
-
Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity.Cancer Res. 2005 May 15;65(10):3986-92. doi: 10.1158/0008-5472.CAN-03-2334. Cancer Res. 2005. PMID: 15899786
-
Solution structure and functional analysis of the cysteine-rich C1 domain of kinase suppressor of Ras (KSR).J Mol Biol. 2002 Jan 18;315(3):435-46. doi: 10.1006/jmbi.2001.5263. J Mol Biol. 2002. PMID: 11786023
-
PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways.Cancer Res. 2006 Feb 1;66(3):1302-12. doi: 10.1158/0008-5472.CAN-05-2341. Cancer Res. 2006. PMID: 16452183
-
KSR and CNK: two scaffolds regulating RAS-mediated RAF activation.Oncogene. 2007 May 14;26(22):3143-58. doi: 10.1038/sj.onc.1210408. Oncogene. 2007. PMID: 17496912 Review.
-
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.Oncogene. 2007 May 14;26(22):3291-310. doi: 10.1038/sj.onc.1210422. Oncogene. 2007. PMID: 17496923 Review.
Cited by
-
SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.Proc Natl Acad Sci U S A. 2023 Nov 21;120(47):e2313137120. doi: 10.1073/pnas.2313137120. Epub 2023 Nov 16. Proc Natl Acad Sci U S A. 2023. PMID: 37972068 Free PMC article.
-
Navigating the ERK1/2 MAPK Cascade.Biomolecules. 2023 Oct 20;13(10):1555. doi: 10.3390/biom13101555. Biomolecules. 2023. PMID: 37892237 Free PMC article. Review.
-
Kinase Suppressor of RAS 1 (KSR1) Maintains the Transformed Phenotype of BRAFV600E Mutant Human Melanoma Cells.Int J Mol Sci. 2023 Jul 23;24(14):11821. doi: 10.3390/ijms241411821. Int J Mol Sci. 2023. PMID: 37511580 Free PMC article.
-
Ras Mitogen-activated Protein Kinase Signaling and Kinase Suppressor of Ras as Therapeutic Targets for Hepatocellular Carcinoma.J Liver Cancer. 2021 Mar;21(1):1-11. doi: 10.17998/jlc.21.1.1. Epub 2021 Mar 31. J Liver Cancer. 2021. PMID: 37384270 Free PMC article. Review.
-
Recent advances in targeting protein kinases and pseudokinases in cancer biology.Front Cell Dev Biol. 2022 Jul 22;10:942500. doi: 10.3389/fcell.2022.942500. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35938171 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous